Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Open Access
- 9 March 2021
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (2) , 599-613
Abstract
Introduction Although alopecia areata (AA) profoundly impacts patients’ physical appearance, emotional state, and daily activities, no treatment approved for AA currently exists. Patient-reported outcome (PRO) instruments currently used to capture patients’ AA experiences do not meet the requirements to support claims of treatment benefit as described in the US Food and Drug Administration’s 2009 PRO guidance. Our objective was to explore the consequences and priority treatment outcomes among individuals with AA and develop a PRO measure consistent with regulatory requirements that assesses these priorities and represents clinical benefit from the AA patient perspective. Methods Targeted literature and instrument reviews informed an initial concept set. Concept elicitation interviews with 20 adults with AA confirmed the relevance and importance of the initial concepts, identified additional relevant concepts, and informed an AA consequence model. Thematic analysis yielded a draft item pool, which was evaluated through two iterative rounds of cognitive debriefing interviews with 16 patients with AA (9 adults; 7 adolescents). Results Hair loss was the primary consequence of importance to patients with AA. Patients emphasized the need to differentiate hair loss by location: scalp, eyebrows, eyelashes, and body. Consequences of AA include difficulty conducting daily activities, particularly outdoor activities and exercise, and emotional impacts such as sadness, frustration, and negative self-image. Following cognitive debriefing interviews, 11 items were included to form the Alopecia Areata Patient Priority Outcome (AAPPO), assessing AA-related symptoms and impacts over the past week. Conclusions The AAPPO is a novel, content-valid PRO that captures the consequences of AA of the highest priority to patients.Keywords
Funding Information
- Pfizer
This publication has 13 references indexed in Scilit:
- Epidemiology and burden of alopecia areata: a systematic reviewClinical, Cosmetic and Investigational Dermatology, 2015
- Side-effects of topical steroids: A long overdue revisitIndian Dermatology Online Journal, 2014
- Development of the Alopecia Areata Symptom Impact ScaleJournal of Investigative Dermatology Symposium Proceedings, 2013
- Quality of life in alopecia areata: a disease‐specific questionnaireJournal of the European Academy of Dermatology and Venereology, 2012
- Development of a disease-specific instrument to measure quality of life in patients with alopecia areataEuropean Journal Of Dermatology, 2012
- Testing and Reducing Skindex-29 Using Rasch Analysis: Skindex-17Journal of Investigative Dermatology, 2006
- Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseasesJournal of Cutaneous Medicine and Surgery, 2001
- Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin DiseasesArchives of Dermatology, 1997
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.1992